Abstract
Systemic AA amyloidosis is a serious complication of many chronic inflammatory disorders. Its association with Crohn's disease implies that the inflammatory burden is high enough for amyloid fibrils to form deposits in tissues. A case is presented in which this complication occurred while the patient was clinically well, with biological and endoscopic markers showing an inactive or mildly active disease under anti-tumor necrosis factor alpha therapy.
Similar content being viewed by others
References
Stokes M, Foster K, Markowitz G, et al. Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20: 1400–6
Lizuka M, Konno S, Horie Y, et al. Infliximab as a treatment for systemic amyloidosis associated with Crohn's disease. Gut 2006; 55: 744–5
Lachmann H, Goodman H, Gilbertson J, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356: 2361–71
Basturk T, Ozagari A, Osturk T, et al. Crohn's disease and secondary amyloidosis: early complication? A case report and review of the literature. J Renal Care 2009; 35(3): 147–50
Denis MA, Reenaers C, Fontaine F, et al. Assessment of endoscopic activity index and biologic inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflamm Bowel Dis 2007; 13(9): 1100–5
Vermeire S, Van Assche G, Rutgeerts P. The role of mucosal healing in the treatment of Crohn's disease and ulcerative colitis. Eur Gastroenterol Rev 2007; 10–11
Tada S, Iida M, Yao T, et al. Intestinal pseudo-obstruction in patients with amyloidosis: clinicopathologic differences between chemical types of amyloid protein. Gut 1993; 34: 1412–17
Boscá M, Pérez-Baylach C, Solis M, et al. Secondary amyloidosis in Crohn's disease: treatment with tumour necrosis factor inhibitor. Gut 2006; 55(2): 294–5
Dember L, Hawkins P, Hazenberg B, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007; 356(23): 2349–60
Sandborn W, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab —a randomized trial. Ann Intern Med 2007; 146(12): 829–39
Horie Y, Chiba M, Miura K, et al. Crohn's disease associated with amyloidosis successfully treated with an elemental diet. J Gastroenterol 1997; 32: 663–7
Lovat B, Madhoo S, Pepys M, et al. Long-term survival in systemic A amyloidosis complicating Crohn's disease. Gastroenterology 1997; 112: 1362–5
Acknowledgments
Dr Fidalgo received honoraria for the submission of the case report, which was funded by Schering-Plough/MSD Portugal. The other authors declare no potential conflicts of interest relevant to this case report. Editorial assistance was provided by Ray Hill of inScience Communications, a Wolters Kluwer business, on behalf of Schering-Plough/MSD Portugal.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fidalgo, C.A., Calado, J. & Cravo, M. Secondary Amyloidosis in a Patient with Long Duration Crohn's Disease Treated with Infliximab. BioDrugs 24 (Suppl 1), 15–17 (2010). https://doi.org/10.2165/11586250-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11586250-000000000-00000